Prestige BioPharma and Dr. Reddy’s unite to supply proposed biosimilar

Date: 2021-12-16   Author: Pankaj Singh  Category: #news

Prestige BioPharma and Dr. Reddy’s unite to supply proposed biosimilar

Singapore-based biopharmaceutical company Prestige BioPharma has recently entered a binding agreement for an exclusive partnership with Dr. Reddy’s Laboratories, a pharmaceutical company.

This latest agreement is geared towards the commercialization and supply of the biopharma company’s proposed biosimilar to treat cancer in select countries in Southeast Asia and Latin America.

The proposed biosimilar of Prestige BioPharma can be prescribed for patients with metastatic gastric and HER2 +ve breast cancer. The treatment works by selectively binding the human epidermal growth factor receptor 2 (HER2), thereby hindering the growth of the cancer cells. Under the license deal, Dr. Reddy’s will gain the exclusive rights to commercialize this biosimilar.

For the record, Prestige BioPharma will ensure the sustainable commercial supply of the biosimilar from its manufacturing facilities located in Osong, South Korea, while the Indian pharmaceutical company will be responsible for local registrations, sales, and marketing in the licensed territories.

According to the CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, M.V. Ramana, the company is thrilled to deliver the life-saving drug to patients, which is in line with its focus on accelerating access to innovative and affordable medicines.

The recent partnership will help the company combine Prestige BioPharma’s established expertise in the field of biosimilars with its growth ambition and commercial strengths in such markets. The agreement will also enable it to create an oncology product portfolio and expand its biosimilar offerings in the emerging markets, Mr. Ramana added.

As per the statement made by Prestige BioPharma’s CEO, Lisa S. Park, the company has shown excitement to enter an exclusive deal and work with Dr. Reddy’s as an ideal partner to commercialize its biosimilar in key Southeast Asian and Latin American regions. With the new collaboration, it is looking forward to further increasing the value of its biosimilar programs in the global markets.

Source credit:

https://www.businesswire.com/news/home/20211215005967/en/Dr.-Reddy%E2%80%99s-and-Prestige-BioPharma-announce-partnership-to-commercialize-biosimilar-for-cancer-treatment-in-select-countries-in-Latin-America-and-Southeast-Asia



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Cardiac Resynchronization Therapy (CRT) Devices Market to 2026 - Growth Trends and Revenue Statistics

Author: Rahul Varpe

A highly analytical qualitative as well as quantitative evaluation of the Cardiac Resynchronization Therapy (CRT) Devices Market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration ...


Medical Products Market Growth Rate, Revenue and Demand Analysis to 2026

Author: Rahul Varpe

An extremely definite evaluation of the Medical Products Market in terms of qualitative as well as quantitative analysis has been covered in this report. The myriad aspects of this industry, having considered its historical and forecast data have ...


Intensive Care Beds Market - Geography Insights and Opportunity Analysis to 2026

Author: Rahul Varpe

The latest study provides an in-depth analysis of the Intensive Care Beds Market focusing on various market definitions, segmentations, sub-segmentations, products, as well as applications. The report further details of the competitive landscape &...